Tag Archives: EU
Thinking of Phase IV Trials? Europe Might See Things Differently…
By Peter O’ Donnell.
With the shadow cast by Mediator across Europe now receding to a focus on the French law courts, the European Union (EU) said in late November that its pharmacovigilance arrangements offer “one of the most advanced and comprehensive systems in the world”. Certainly the EU’s legislative framework has been significantly boosted over [...]
Posted in Europe, Global, Guest Blog, R&D Also tagged Clinical Trials, European Union, pharmacovigilance, R&D Leave a comment
European Pharma Bets on Greek Salvation
The French philosopher Pascal calculated that it was better to believe in God than to disbelieve. After offering the country a €2.88 billion cap on drug spending, it looks like European pharma is taking that view with regard to Greece. Reflector reports.
The European pharma industry looks like it is accepting Pascal’s Wager in Greece. It [...]
Posted in Europe, Global, Guest Blog Also tagged austerity, Cuts, EC, EFPIA, Europe, Greece Leave a comment
EFPIA Calls for New Deal in Europe
EFPIA president Andrew Witty is hoping that the deepening European economic crisis will impel European leaders towards more courageous and radical solutions, writes Reflector.
With the European economic and financial crisis deepening all the time, the healthcare sector in general — and the pharmaceutical sector in particular — faces further constraints from cost cutting. As European [...]
Posted in Europe, Guest Blog, Op-Ed, Regulatory, healthcare Also tagged EC, EFPIA, EPHA, euro crisis, eurozone crisis, Reflector Leave a comment
European Pharma 1981-2011: Survival of the Fittest?
This month sees Pharmaceutical Executive magazine reach its 30th birthday. In line with that milestone, Reflector assesses what the last three decades have meant for European pharma — and shows how the game has changed beyond recognition.
Thirty years is a long time in any industry. The coalmining industry, the market for air travel, or telecommunications [...]
Posted in Emerging Markets, Europe, Global, Guest Blog, IP, Pharm Exec Magazine, R&D, Regulatory, healthcare, leadership Also tagged European Union, GlaxoSmithKline, Hoffman-La Roche, Merck Sharp Dohme, parallel trading, Sanofi Leave a comment

Saving Greece's Healthcare System: A Harbinger for Europe?